Led · Series A · May 2022

Headquartered in Perth, Western Australia, OncoRes Medical is a medical device company focused on eliminating repeat operations after breast-conserving surgery. Its core product, Elora™, uses Quantitative Micro-Elastography (QME) to provide surgeons with real-time, high-resolution mechanical and optical maps of tissue stiffness inside the surgical cavity, enabling more complete tumour removal. The device received FDA Breakthrough Device Designation in 2020, positioning it for an expedited U.S. regulatory pathway. The company has launched an Australian multi-site clinical trial that will enroll more than 110 patients to generate interventional data. Capital from the latest raise will fund this trial, advance product development, support manufacturing for a U.S. pivotal trial, and expand the team. OncoRes also plans to explore additional cancer indications such as prostate cancer. Medtech veteran Renee Ryan recently joined the board to guide U.S. market entry and long-term commercialization.

Led · Series A · Mar 2022

Baymatob develops Oli, a wireless, wearable device that monitors maternal and fetal signals and aims to analyse up to fifteen pregnancy and birth conditions and complications. Targeted conditions include postpartum haemorrhage, fetal distress, stillbirth risk and labour progression. The company is conducting pivotal clinical trials across seven sites in Australia and the United States and is advancing regulatory submissions with the TGA and FDA. Baymatob plans to establish manufacturing operations and its headquarters in Australia. Financially, the company has raised $13 million in private capital plus more than $9.5 million in non-dilutive grants and completed a $6.5 million Series A3 in 2025.